natgillin/translations-raw huggingface dataset:
Effekten af rivastigmin ved demens associeret med Parkinsons sygdom, er demonstreret i et 24ugers multicenter, dobbelt-blindt, placebo-kontrolleret hovedstudie og dets 24-ugers open-label forlængelsesfase.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Effekten af rivastigmin ved demens, associeret med Parkinsons sygdom, er demonstreret i et 24-ugers multicenter, dobbelt-blindt, placebo-kontrolleret hovedstudie og dets 24-ugers open-label forlængelsesfase.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Effekten af rivastigmin ved demens, der er associeret med Parkinsons sygdom, er demonstreret i et 24- ugers multicenter, dobbelt-blindt, placebo-kontrolleret hovedstudie og dets 24-ugers open-label forlængelsesfase.
The efficacy of rivastigmine in dementia associated with Parkinson’s disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Effekten af rivastigmin ved demens, der er associeret med Parkinsons sygdom, er demonstreret i et 24-ugers multicenter, dobbelt-blindt, placebo-kontrolleret hovedstudie og dets 24-ugers open-label forlængelsesfase.
The efficacy of rivastigmine in dementia associated with Parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase.
Effekten af sildenafil bør overvåges nøje hos patienter, der samtidigt anvender potente CYP3A4- induktorer som carbamazepin, phenytoin, phenobarbital, perikon og rifampicin.
Efficacy of sildenafil should be closely monitored in patients using concomitant potent CYP3A4 inducers, such as carbamazepine, phenytoin, phenobarbital, St John’s wort and rifampicine.
Effekten af Silgard imod den kombinerede forekomst af HPV 16- eller 18-relateret persisterende infektion, kondylomer, vulva- og vaginallæsioner, alle grader af CIN, AIS og cervixcancer var 84,7 % (95 % CI: 67,5, 93,7).
The efficacy of Silgard against the combined incidence of HPV 16- or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 84.7% (95% CI: 67.5, 93.7).
Effekten af Silgard imod den kombinerede forekomst af HPV 6-, 11-, 16- og 18-relateret persisterende infektion, kondylomer, vulva- og vaginallæsioner og alle grader af CIN, AIS og cervixcancere var 47,2 % (95 % CI: 33,5; 58,2).
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 47.2% (95% CI: 33.5, 58.2).
Effekten af Silgard imod den kombinerede forekomst af HPV 6-, 11-, 16- og 18-relateret persisterende infektion, kondylomer, vulva- og vaginallæsioner, alle grader af CIN, AIS og cervixcancer var 88,7 % (95 % CI: 78,1; 94,8).
The efficacy of Silgard against the combined incidence of HPV 6-, 11-, 16-, or 18-related persistent infection, genital warts, vulvar and vaginal lesions, CIN of any grade, AIS, and cervical cancers was 88.7% (95% CI: 78.1, 94.8).
Effekten af simeprevir i kombination med peginterferon alfa og ribavirin blev undersøgt hos behandlingsnaive eller behandlingserfarne (efter tidligere interferon-baseret behandling) patienter med HCV-genotype 1- eller 4-infektion med eller uden samtidig HIV 1-infektion (tabel 17 og 18).
The efficacy of simeprevir in combination with peginterferon alfa and ribavirin was evaluated in patients with HCV genotype 1 or 4 infection, with or without HIV-1 co-infection, who were treatment-naïve or treatment-experienced (following prior interferon-based therapy) (tables 17 and 18).
Effekten af Simponi blev demonstreret i tre randomiserede, dobbeltblindede, placebokontrollerede multicenter-studier med over 1.500 patienter ≥ 18 år med moderat til svær aktiv RA, diagnosticeret i henhold til American College of Rheumatology (ACR)-kriterier i mindst 3 måneder op til screening.
The efficacy of Simponi was demonstrated in three multi-centre, randomised, double-blind, placebo-controlled studies in over 1500 patients ≥ 18 years of age with moderately to severely active RA diagnosed according to American College of Rheumatology (ACR) criteria for at least 3 months prior to screening.
Effekten af Sprimeo på warfarins farmakokinetik er ikke blevet evalueret.
The effects of Sprimeo on warfarin pharmacokinetics have not been evaluated.
Effekten af Tekturna på warfarins farmakokinetik er ikke blevet evalueret.
The effects of Tekturna on warfarin pharmacokinetics have not been evaluated.
Effekten af trastuzumabemtansin hos patienter med HER2-positiv, uhelbredelig lokalt fremskeden brystkræft eller metastatisk brystkræft er undersøgt i et enkeltarmet, ublindet fase II-studie.
A Phase II, single-arm, open-label study evaluated the effects of trastuzumab emtansine in patients with HER2-positive incurable, LABC or MBC.
Effekten af Triumeq hos hiv-inficerede, behandlingsnaive personer er baseret på analyser af data fra to randomiserede, internationale, dobbeltblindede, aktivt-kontrollerede studier, SINGLE (ING114467) og SPRING-2 (ING113086) og det internationale åbne, aktivt kontrollerede studie FLAMINGO (ING114915).
The efficacy of Triumeq in HIV-infected, therapy naive subjects is based on the analyses of data from two randomized, international, double-blind, active-controlled trials, SINGLE (ING114467) and SPRING-2 (ING113086) and the international, open-label, active-controlled trial FLAMINGO (ING114915).
Effekten af umeclidinium/vilanterol på QT-intervallet blev vurderet i et placebo- og aktiv (moxifloxacin)- kontrolleret QT-studie, hvor umeclidinium/vilanterol 113/22 mikrogram eller 500/100 mikrogram (afdelt dosis med 8 gange den anbefalede dosis af umeclidinium og 4 gange den anbefalede dosis af vilanterol) blev administreret én gang daglig i 10 dage, hos 103 raske personer.
The effect of umeclidinium/vilanterol on the QT interval was evaluated in a placebo and active (moxifloxacin) controlled QT study involving once daily administration of umeclidinium/vilanterol 113/22 micrograms or 500/100 micrograms (pre-dispensed dose with umeclidinium at eight times the recommended dose and vilanterol at four times the recommended dose) for 10 days in 103 healthy volunteers.
Effekten af vaccinen er påvist ved middel til høje værdier af maternelle antistoffer hos smågrise.
The efficacy of the vaccine in the face of intermediate to high levels of maternally derived antibodies in piglets has been demonstrated.
Effekten af vaccinen i protokolanalysen var en reduktion på 9% (95% CI: 3, 15) over for tilbagevendende AOM (defineret som 3 tilfælde i løbet af 6 måneder eller 4 tilfælde i løbet af et år) eller en reduktion på 23% (95% CI: 7, 36) over for tilbagevendende AOM (5 tilfælde i løbet af 6 måneder eller 6 tilfælde i løbet af et år).
The effect of the vaccine in the per-protocol analysis was a 9 % reduction (95 % CI: 3, 15) in recurrent AOM (defined as 3 episodes in six months or 4 episodes in one year) or a 23 % (95 % CI: 7,36) reduction for recurrent AOM (5 episodes in six months or 6 episodes in one year).
Effekten af vaccinen mod 6-måneders persisterende infektion med HPV-16/18 (relevant surrogatmarkør for cervixcancer) er opsummeret i den følgende tabel.
Vaccine efficacy against 6 month persistent infection with HPV-16/18 (relevant surrogate marker for cervical cancer) is summarised in the following table.
Effekten af vaccinen mod 6-måneders persisterende infektion var 23,2 % (97,7 % CI [-23,3; 52,5]) for HPV-31 og 67,7 % (97,7 % CI [35,9; 84,9]) for HPV-45 i TVC-kohorten.
Vaccine efficacy against 6-month persistent infection was 23.2% (97.7% CI [-23.3; 52.5]) for HPV-31 and 67.7% (97.7% CI [35.9; 84.9]) for HPV-45 in the TVC.
Effekten af vaccinen mod 6-måneders persisterende infektion var 79,1 % (97,7 % CI [27,6; 95,9]) for HPV-31 and 76,9 % (97,7 % CI [18,5; 95,6]) for HPV-45 i ATP-kohorten (3 vaccinedoser, DNA- negative ved måned 0 og 6 for de relevante HPV-typer).
Vaccine efficacy against 6-month persistent infection was 79.1% (97.7% CI [27.6; 95.9]) for HPV-31 and 76.9% (97.7% CI [18.5; 95.6]) for HPV-45 in the ATP cohort (3 doses of vaccine, DNA negative at months 0 and 6 for the relevant HPV type).
Effekten af vaccinen mod det primære endepunkt CIN2+ ved slutningen af studiet er anført i tabel 1.
Vaccine efficacy against the primary endpoint CIN2+ at the end of study is presented in Table 1.
Effekten af vaccinen mod det primære endepunkt CIN2+ ved slutningen af studiet er anført i tabel 1.
Vaccine efficacy against the primary endpoint CIN2+ is presented in Table 1.
Effekten af vaccinen mod high-grade celleforandringer blev vist i TVC-kohorten og i kohorten TVC-naive ved slutningen af studiet (tabel 5).
In the TVC and TVC-naïve cohorts, the vaccine’s efficacy was demonstrated against high-grade cervical lesions at end of study (Table 5).
Effekten af Vectibix i anden-linje-behandling i kombination med irinotecan, fluoruracil (5-FU) og leucovorin (FOLFIRI) blev undersøgt i et randomiseret, kontrolleret studie med 1.186 patienter med mCRC med de primære endepunkter OS og PFS.
The efficacy of Vectibix in second-line in combination with irinotecan, 5-fluorouracil (5-FU) and leucovorin (FOLFIRI) was evaluated in a randomised, controlled trial of 1,186 patients with mCRC with the primary endpoints of OS and PFS.
Effekten af Vectibix i kombination med oxaliplatin, fluoruracil (5-FU) og leucovorin (FOLFOX) blev undersøgt i et randomiseret, kontrolleret studie med 1.183 patienter med mCRC, hvor det primære endepunkt var PFS.
The efficacy of Vectibix in combination with oxaliplatin, 5-fluorouracil (5-FU), and leucovorin (FOLFOX) was evaluated in a randomised, controlled trial of 1,183 patients with mCRC with the primary endpoint of PFS.
Effekten af veterinærlægemidlet ved den anbefalede dosis er ikke tilstrækkelig til behandling af parasitær sygdom forårsaget af Capillaria spp.
The efficacy of the veterinary medicinal product at the recommended dosage is not sufficient for the treatment of infections with Capillaria spp.
Effekten af Vimpat som tillægsbehandling ved de anbefalede doser (200 mg daglig, 400 mg daglig) blev dokumenteret i 3 randomiserede, placebo-kontrollerede, multicenter-kliniske forsøg med en vedligeholdelsesperiode på 12 uger.
The efficacy of Vimpat as adjunctive therapy at recommended doses (200 mg/day, 400 mg/day) was established in 3 multicenter, randomized, placebo-controlled clinical trials with a 12-week maintenance period.
Effekten af voriconazol sammenlignet med behandling med amphotericin B efterfulgt af fluconazol i primær behandling af candidæmi blev vist i et åbent komparativt studie.
The efficacy of voriconazole compared to the regimen of amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study.
Effekten af voriconazol sammenlignet med behandling med amphotericin B efterfulgt af fluconazol i primær behandling af candidæmi, blev vist i et åbent komparativt studie.
The efficacy of voriconazole compared to the regimen of amphotericin B followed by fluconazole in the primary treatment of candidaemia was demonstrated in an open, comparative study.
Effekten af vortioxetin 10 og 20 mg/dag versus agomelatin 25 og 50 mg/dag blev derudover vist i et 12-ugers dobbeltblindet, sammenlignende studie med fleksibel dosis hos patienter med moderate til svære depressive episoder.
The efficacy of vortioxetine 10 or 20 mg/day was further demonstrated in a 12-week, double-blind, flexible-dose comparative study versus agomelatine 25 or 50 mg/day in patients with MDD.
Effekten af Xeplion til opretholdelse af symptomkontrol og forsinkelse af recidiv af skizofreni blev klarlagt i et længerevarende dobbeltblindt, placebokontrolleret forsøg med fleksible doser, der omfattede 849 ikke-ældre, voksne forsøgspersoner, som opfyldte DSM-IV-kriterierne for skizofreni.
The efficacy of Xeplion in maintaining symptomatic control and delaying relapse of schizophrenia was established in a longer-term double-blind, placebo-controlled, flexible-dose study involving 849 non-elderly adult subjects who met DSM-IV criteria for schizophrenia.
Effekten af Xeristar er vist med den anbefalede faste dosis på 60 mg én gang daglig i tre ud af tre randomiserede dobbeltblinde, placebo- kontrollerede studier på voksne akutte ambulante patienter med moderate til svære depressioner.
The efficacy of Xeristar at the recommended dose of 60 mg once a day was demonstrated in three out of three randomised, double-blind, placebo-controlled, fixed dose acute studies in adult outpatients with major depressive disorder.
Effekten af YENTREVE er ikke blevet undersøgt i mere end 3 måneder i placebokontrollerede studier.
The efficacy of YENTREVE has not been evaluated for longer than 3 months in placebo-controlled studies.
Effekten af Zyclara blev undersøgt i to dobbeltblinde, randomiserede, kliniske forsøg med vehikel som kontrol.
The efficacy of Zyclara was studied in two double-blind, randomized, vehicle-controlled clinical studies.
Effekten baseret på data fra studiet kan ses i nedenstående tabel.
Efficacy results are presented in the table below:
Effekten blev bestemt på grundlag af en dyrlægeundersøgelse og ejerens vurdering.
The effectiveness was determined based on examinations by a veterinarian and assessments by the animal’s owner.
Effekten blev fastslået ved hjælp af ADAS-Cog (Alzheimers Disease Assessment Scale - Cognitive subscale, en præstationsbaseret måling af kognition) og ADCS-IADL (Alzheimers Disease Cooperative Study - Instrumental Activities of Daily Living) der vurderer instrumentale aktiviteter, som omfatter vedligeholdelse af budget, tilberedning af måltider, indkøb, evnen til at orientere sig til omgivelserne, evnen til at klare sig uden opsyn.
Efficacy was established by the use of ADAS-Cog (Alzheimer’s Disease Assessment Scale – Cognitive subscale, a performance-based measure of cognition) and the ADCS-IADL (Alzheimer’s Disease Cooperative Study – Instrumental Activities of Daily Living) assessing instrumental activities which include maintaining finances, meal preparation, shopping, ability to orient oneself to surroundings, ability to be left unattended.
Effekten blev også opretholdt hos regorafenib-naive patienter (hazard ratio: 0,69, 95% CI [0,57 til 0,83]).
The effect was also maintained in regorafenib-naive patients (hazard ratio: 0.69, 95% CI [0.57 to 0.83]).
Effekten blev også vurderet i et randomiseret, dobbeltblind, placebokontrolleret studie hos 94 patienter med fistulerende Crohns sygdom, som havde fistler af mindst 3 måneders varighed.
The efficacy was assessed in a randomised, double-blinded, placebo-controlled study in 94 patients with fistulising Crohn’s disease who had fistulae that were of at least 3 months’ duration.
Effekten blev opretholdt i 52 uger (RA-I) og 24 (RA-II) Af de
Responses were maintained through Weeks 52 (RA-I) and 24 (RA-II).
Effekten blev progressivt mindsket ved administration af en verapamilformulering med forlænget frigivelse (stigning i Cmax med omkring 90 % og i AUC med omkring 70 %) eller ved steady state ved administration af multiple doser af verapamil (stigning i Cmax med omkring 60 % og i AUC med omkring 50 %).
The effect was progressively decreased with administration of an extended release formulation (increased of Cmax by about 90 % and AUC by about 70 %) or administration of multiple doses of verapamil (increased of Cmax by about 60 % and AUC by about 50 %).
Effekten blev undersøgt hos i alt 390 hæmodynamisk stabile voksne patienter, som havde haft atrieflimren i kort tid, herunder patienter med hypertension (40,5%), iskæmisk hjertesygdom (12,8%), valvulær hjertesygdom (9,2%) og venstresidig hjerteinsufficiens (10,8%).
Efficacy was studied in a total of 390 haemodynamically stable adult patients with short duration atrial fibrillation including patients with hypertension (40.5%), ischaemic heart disease (12.8%), valvular heart disease (9.2%) and CHF (10.8%).
Effekten blev undersøgt hos patienter med atrieflimren efter kardiel kirurgi i ACT II, en fase 3, dobbeltblindet, placebokontrolleret, parallel gruppeundersøgelse (ACT II) hos 150 patienter med vedvarende atrieflimren (3-72 timers varighed), som indtrådte mellem 24 timer og 7 dage efter koronar bypasskirurgi og/eller valvulær kirurgi.
Efficacy was studied in patients with atrial fibrillation after cardiac surgery in ACT II, a phase 3, double-blind, placebo-controlled, parallel group study (ACT II) in 150 patients with sustained atrial fibrillation (3 hours to 72 hours duration) that occurred between 24 hours and 7 days post coronary artery bypass graft and/or valvular surgery.
Effekten blev vedligeholdt hos alle forsøgspersoner uanset seropositivitetsstatus for alle vaccine-HPV-typer under hele studiet (op til 67 måneder efter dosis 3, median opfølgningsperiode på 43 måneder efter dosis 3.
Efficacy was maintained in all subjects regardless of seropositivity status for any vaccine HPV type through the end of the study (up to 67 months postdose 3; median follow-up duration of 43 months postdose 3).
Effekten blev vurderet ved hjælp af PANSS.
Efficacy was evaluated using the PANSS.
Effekten blev vurderet ved målinger af lungefunktion, symptomatiske resultater, sygdomsspecifik helbredstilstand, brug af anfaldsmedicin og exacerbationer.
Efficacy was assessed by measures of lung function, symptomatic outcomes, disease-specific health status, rescue medication use, and exacerbations.
Effekten blevet fastslået ved hjælp af to uafhængige skalaer, som blev vurderet ved regelmæssige intervaller i løbet af en 6-måneders behandlingsperiode, som vist i tabel 5 nedenfor: ADAS-Cog, en måling af kognition og den globale måling ADCS-CGIC (Alheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer’s Disease Cooperative Study- Clinician’s Global Impression of Change).
Effekten blevet fastslået ved hjælp af to uafhængige skalaer, som blev vurderet ved regelmæssige intervaller i løbet af en 6-måneders behandlingsperiode, som vist i tabel 5 nedenfor: ADAS-Cog, en måling af kognition og den globale måling ADCS-CGIC (Alheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change).
Effekten blevet fastslået ved hjælp af to uafhængige skalaer, som blev vurderet ved regelmæssige intervaller i løbet af en 6-måneders behandlingsperiode, som vist i tabel 5 nedenfor: ADAS-Cog, en måling af kognition og den globale måling ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer’s Disease Cooperative Study- Clinician’s Global Impression of Change).
Effekten blevet fastslået ved hjælp af to uafhængige skalaer, som blev vurderet ved regelmæssige intervaller i løbet af en 6-måneders behandlingsperiode, som vist i tabel 5 nedenfor: ADAS-Cog, en måling af kognition og den globale måling ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change).
Effekten er baseret på tidspunktet for tumorprogression (TTP) og stigning i overlevelse med GIST på henholdsvis progressions-fri overlevelse og objektiv responsrate for behandlingsnaiv og cytokin- refraktær mRCC og progressions-fri overlevelse ved pNET.
Efficacy is based on time to tumour progression (TTP) and an increase in survival in GIST, on progression free survival and objective response rates for treatment-naïve and cytokine-refractory MRCC respectively, and on progression free survival for pNET.
Effekten er blevet fastslået ved hjælp af to uafhængige skalaer, som blev vurderet ved regelmæssige intervaller i løbet af en 6-måneders behandlingsperiode, som vist i tabel 5 nedenfor: ADAS-Cog, en måling af kognition og den globale måling ADCS-CGIC (Alzheimer’s Disease Cooperative Study-Clinician’s Global Impression of Change).
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative Study- Clinician's Global Impression of Change).
Effekten er blevet vurderet på baggrund af foreløbige resultater på hos kyllinger.
Efficacy has been evaluated on the basis of preliminary results in chickens.
Effekten er dog af en størrelsesorden, så det ikke er sandsynligt, at det medfører klinisk betydningsfulde lægemiddelinteraktioner.
However, the magnitude of the effect seems unlikely to result in clinically important drug-drug interactions.
Effekten er ikke fastslået hos får, som vejer mindre end 10 kg.
The efficacy has not been established in sheep weighing less than 10 kg.
Effekten har væ ret demonstreret med eller uden samtidig brug af methotrexat.
Efficacy has been demonstrated with or without concomitant use of methotrexate.
Effekten hos svin med en meget høj koncentration af maternelle antistoffer, der f.eks. skyldes vaccination af dyrets moder, er ikke påvist.
The benefit of the vaccination of pigs with very high levels of maternally-derived antibodies, e.g. due to vaccination of their mothers, has not been demonstrated.
Effekten i første leveår stiger progressivt med stigende sværhedsgrad af sygdom, indtil 100 % (95 % CI: 84,7; 100) for Vesikari-score ≥ 17.
Vaccine efficacy during the first year of life progressively increased with increasing disease severity, reaching 100% (95% CI: 84.7;100) for Vesikari scores 17.
Effekten imod anal intraepitelial neoplasi (AIN grad 1/2/3) og analcancer samt intraanal persisterende infektion blev vurderet i en undergruppe på 598 mænd (GARDASIL = 299; placebo = 299) i Protokol 020, der identificerede sig selv som mænd, som har sex med mænd (MSM-population).
In a subset of 598 men (GARDASIL = 299; placebo = 299) in Protocol 020 who self-identified as having sex with men (MSM) efficacy against anal intraepithelial neoplasia (AIN grades 1/2/3) and anal cancer, and intra-anal persistent infection was evaluated.
Effekten mod alvorlig rotavirus- gastroenteritis, som krævede hospitalisering var 100 % (95 % CI: 72,4; 100,0).
The efficacy against severe RV gastro-enteritis requiring hospitalisation was 100% (95% CI: 72.4; 100.0).
Effekten mod alvorlig rotavirus- gastroenteritis, som krævede hospitalisering, var 100 % (95 % CI: 72,4; 100,0).
The efficacy against severe RV gastro-enteritis requiring hospitalisation was 100% (95% CI: 72.4; 100.0).